Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab induction therapy in plaque-type psoriasis
NCT00230529Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of infliximab in plaque psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of patients achieving a >= 75% improvement in PASI score from baseline at 10 weeks. Status: completed.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00230529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230529.